ºÏ¹ÌÀÇ ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀå º¸°í¼­ : ¹üÀ§, ºÎ¹®, ¿ªÇÐ, °æÀï ºÐ¼®(2021-2031³â)
North America Pharmacovigilance and Drug Safety Software Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis
»óǰÄÚµå : 1819687
¸®¼­Ä¡»ç : The Insight Partners
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 210 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,450 £Ü 4,962,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.
US $ 4,450 £Ü 6,400,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,450 £Ü 7,838,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ºÏ¹ÌÀÇ ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀº 2023³â ¾à 1¾ï3¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í 2023³âºÎÅÍ 2031³â±îÁöÀÇ ¿¹Ãø ±â°£ µ¿¾È 7.8%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î 2031³â±îÁö ¾à 1¾ï 8,272¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

ÀǾàǰ ºÎÀÛ¿ë Áõ°¡

ÀǾàǰ ºÎÀÛ¿ë(ADR) Áõ°¡´Â ºÏ¹ÌÀÇ ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â Áß¿äÇÑ ¿äÀÎÀÔ´Ï´Ù. ¸¸¼º ÁúȯÀÇ À¯º´·üÀº »ó½Â °æÇâÀÌ ÀÖÀ¸¸ç, ó¹æµÇ´Â ¾à¹°ÀÇ ¼ö°¡ Áõ°¡Çϰí Àֱ⠶§¹®¿¡ ADRÀÌ ¹ß»ýÇÒ °¡´É¼ºÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¸ðµç ÀǾàǰÀÌ ºÎÀÛ¿ëÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù´Â Á¡À» °¨¾ÈÇÒ ¶§, ÀǾàǰÀÌ Ã³¹æ µÉ ¶§¸¶´Ù öÀúÇÑ À§Çè ÇýÅà ºÐ¼®À» ¼öÇàÇÏ´Â °ÍÀÌ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ADRÀº ƯÈ÷ Ä¡·á ¿ä¹ýÀÇ º¹À⼺, Àα¸ °í·ÉÈ­, ¿©·¯ ¸¸¼º ÁúȯÀÇ È®»êÀ¸·Î Çö´ë °Ç°­ °ü¸®¿¡ Å« ¾î·Á¿òÀ» °Þ°í ÀÖ½À´Ï´Ù.

¾à¹°°¨½Ã ¼ÒÇÁÆ®¿þ¾î´Â ÀÇ·á Á¦°ø¾÷ü ¹× Á¦¾à ȸ»ç°¡ ADR¿¡ ´ëÇÑ µ¥ÀÌÅ͸¦ ü°èÀûÀ¸·Î ¼öÁý, ºÐ¼® ¹× º¸°íÇÒ ¼ö ÀÖµµ·Ï ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÀÌ ¼ÒÇÁÆ®¿þ¾î´Â ¹Ì±¹ ½ÄǰÀǾ౹ÀÇ ºÎÀÛ¿ë º¸°í ½Ã½ºÅÛ(FAERS) µ¥ÀÌÅÍ¿¡¼­µµ ¾Ë ¼ö ÀÖµíÀÌ ADRÀÌ ÃÊ·¡ÇÏ´Â °úÁ¦¸¦ ÇØ°áÇÏ´Â µ¥ ÇʼöÀûÀ̸ç, 2022³â¿¡¸¸ 125¸¸ °ÇÀÌ ³Ñ´Â ½É°¢ÇÑ ºÎÀÛ¿ë »ç·Ê¿Í 17¸¸ 5,000¸í ÀÌ»óÀÇ »ç¸Á »ç·Ê°¡ º¸°íµÇ¾ú½À´Ï´Ù.

Å׿ÀÇʸ°°ú ¸¶Å©·Î¶óÀ̵å°è Ç×»ýÁ¦ÀÇ »óÈ£ÀÛ¿ë°ú ºñŸ¹Î K ¼·Ãë·® Áõ°¡¿Í °°Àº ƯÁ¤ ¾à¹°ÀÇ »óÈ£ÀÛ¿ëÀº ADR°ú °ü·ÃÀÌ ÀÖ½À´Ï´Ù. ADRÀÇ º¸°í °Ç¼ö°¡ Áõ°¡ÀÇ ±æÀ» µû¶ó°¡´Â °¡¿îµ¥, Á¦¾àȸ»ç, ÀÇ·á Á¦°øÀÚ, ±ÔÁ¦±â°ü¿¡ ´ëÇÑ ÀǾàǰ ¾ÈÀü¼º °¨½Ã¡¤º¸°í ÇÁ·Î¼¼½ºÀÇ °­È­¿¡ ´ëÇÑ ¾Ð·ÂÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î´Â ºÎÀÛ¿ëÀÇ °ËÃâ, Æò°¡, ¿¹¹æÀ» °£¼ÒÈ­ÇÏ¿© ½Å¼ÓÇÑ ´ëÀÀ°ú º¸´Ù Á¤È®ÇÑ À§Çè Æò°¡¸¦ ÃËÁøÇÕ´Ï´Ù. ±× °á°ú, ADR ¹ß»ý·ü Áõ°¡°¡ ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù.

ºÏ¹Ì ½ÃÀå °³¿ä

ºÏ¹ÌÀÇ ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ±¸ºÐµË´Ï´Ù. ºÏ¹Ì´Â ÀǾàǰ°ú ÀǾàǰÀÇ ¾ÈÀü¼º¿¡ °üÇÑ ±ÔÁ¦¸¦ ½Å¼ÓÇÏ°Ô µµÀÔÇÑ Áö¿ªÀ¸·Î Àνĵǰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÌ Áö¿ª¿¡¼­´Â ÀǾàǰ ºÎ¹®ÀÇ µðÁöÅÐÈ­°¡ ±Þ¼ÓÈ÷ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. Canada Health Infoway¿¡ µû¸£¸é, ij³ª´Ù Á¦¾à ȸ»ç´Â µðÁöÅÐ °Ç°­ ¼­ºñ½ºÀÇ Ã¤ÅÃÀ» ´Ã¸®°í ÀÖÀ¸¸ç, ÀÌ´Â ¾ÕÀ¸·Î ¼ö³â°£ ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Á¦¾à ¾÷°è¿¡¼­ÀÇ µðÁöÅÐÈ­ÀÇ ÁøÀüÀº ÀǾàǰÀÇ È¿°úÀûÀÎ ¸ð´ÏÅ͸µÀÇ Çʿ伺À» ³ô¿© ¾à¹°°¨½Ã ¼Ö·ç¼Ç ¼ö¿ä¸¦ Áõ°¡½Ãų °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

º¸°íµÇ´Â ºÎÀÛ¿ëÀÇ ¾çÀÌ Áõ°¡ÇÔ¿¡ µû¶ó, ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü Àü¹®°¡µéÀº ÀÌ µ¥ÀÌÅ͸¦ Á¤È®Çϰí È¿À²ÀûÀ¸·Î Æò°¡ÇÏ´Â µ¥ ´õ Å« °úÁ¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ºÎÀÛ¿ë µ¥ÀÌÅÍÀÇ Á¤È®Çϰí ü°èÀûÀÎ ºÐ¼®À» º¸ÀåÇϸ鼭 ÀÌ·¯ÇÑ Àü¹®°¡ÀÇ ÀÛ¾÷ ºÎ´ãÀ» ÁÙÀ̱â À§Çؼ­´Â ÷´Ü ±â¼ú µµÀÔÀÌ ÇʼöÀûÀÔ´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­ ºÐ¼®

ºÏ¹ÌÀÇ ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀº Á¦°ø Á¦Ç°, ¹èÆ÷, ±â¾÷ ±Ô¸ð, ÇüÅÂ, ±â´É, ÃÖÁ¾ »ç¿ëÀÚ, ±¹°¡ µî ´Ù¾çÇÑ ¿äÀο¡ µû¶ó ºÐ·ùÇÒ ¼ö ÀÖ½À´Ï´Ù.

1. Á¦°ø Á¦Ç° : ½ÃÀåÀº ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º·Î ³ª´µ¾î 2023³â¿¡´Â ¼ÒÇÁÆ®¿þ¾î ºÐ¾ß°¡ Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

2. ¹èÆ÷ : ½ÃÀåÀº Ŭ¶ó¿ìµå ±â¹Ý°ú On-Premise ¼Ö·ç¼ÇÀ¸·Î ±¸ºÐµÇ¾úÀ¸¸ç, 2023³â¿¡´Â Ŭ¶ó¿ìµå ¼Ö·ç¼ÇÀÌ ½ÃÀå Á¡À¯À²À» µ¶Á¡Çß½À´Ï´Ù.

3. ±â¾÷ ±Ô¸ð : ½ÃÀåÀº ´ë±â¾÷°ú Áß¼Ò±â¾÷À¸·Î ºÐ·ùµÇ¾úÀ¸¸ç, 2023³â¿¡´Â ´ë±â¾÷ÀÌ Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

4. ÇüÅ : ¼ÒÇÁÆ®¿þ¾î´Â Ç¥ÁØ ÇüÅÂ¿Í ÁÖ¹®À» ¹Þ¾Æ¼­ ¸¸µé¾îÁø ÇüŸ¦ °¡Áö°í ÀÖ°í ½ÃÀå¿¡¼­´Â Ç¥ÁØ ÇüŰ¡ ´ëÁßÀûÀÔ´Ï´Ù.

5. ±â´É¼º : ½ÃÀåÀº ½ÅÈ£ ¹× À§Çè °ü¸®, ¹®Á¦ ÃßÀû, »ç·Ê °ü¸®, ÀÓ»ó ¾ÈÀü °ü¸®, ǰÁú ¹× ±ÔÁ¤ Áؼö, °Ç°­ °ü¸® ºÐ¼® µî ´Ù¾çÇÑ ±â´ÉÀ» Æ÷ÇÔÇϰí ÀÖÀ¸¸ç, 2023³â¿¡´Â ½ÅÈ£ ¹× À§Çè °ü¸®°¡ °¡Àå Å« ºÎ¹®ÀÌ µÇ¾ú½À´Ï´Ù.

6. ÃÖÁ¾ »ç¿ëÀÚ : ÁÖ¿ä ÃÖÁ¾ »ç¿ëÀÚ´Â Á¦¾à ¹× »ý¸í °øÇРȸ»ç, ÀǾàǰ °³¹ß ¾÷¹« ¼öŹ ±â°ü, ºñÁî´Ï½º ÇÁ·Î¼¼½º ¾Æ¿ô¼Ò½Ì ȸ»ç µîÀ» Æ÷ÇÔÇϸç Á¦¾à ¹× »ý¸í °øÇÐ ±â¾÷ÀÌ ½ÃÀå Á¡À¯À²À» À̲ø°í ÀÖ½À´Ï´Ù.

7. ±¹°¡º° : ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ±¸ºÐµÇ¾úÀ¸¸ç, 2023³â¿¡´Â ¹Ì±¹ÀÌ ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù.

½ÃÀåÀÇ ÁÖ¿ä ±â¾÷

ºÏ¹ÌÀÇ Pharma Cobigilance ¹× Á¦¾à ¾ÈÀü ¼ÒÇÁÆ®¿þ¾î ½ÃÀå¿¡¼­ Veeva Systems Inc., IQVIA Holdings Inc., AB Cube SAS, ArisGlobal LLC, Oracle Corp., Max Application, ICON Plc, Cognizant Technology Solutions Corp, Accenture Plc, Syneos Health Corp., GenLacme Holdings, Parexel International Corp, Qinecsa Solutions, Clinevo Technologies µî ¿©·¯ À¯·Â ±â¾÷µéÀÌ È°¾àÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¾÷µéÀº ÀÌ Áö¿ª¿¡¼­ÀÇ ÀǾàǰ ¾ÈÀü¼º°ú ¾à¹°°¨½ÃÀÇ ½ÇõÀ» °­È­ÇÏ´Â Çõ½ÅÀûÀÎ ¼Ö·ç¼Ç °³¹ßÀÇ ÃÖÀü¼±¿¡ ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ºÏ¹ÌÀÇ ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀå »óȲ

Á¦5Àå ºÏ¹ÌÀÇ ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀå : ÁÖ¿ä ½ÃÀå ¿ªÇÐ

Á¦6Àå ºÏ¹ÌÀÇ ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ºÐ¼®

Á¦7Àå ºÏ¹ÌÀÇ ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ºÐ¼® : Á¦°ø Á¦Ç°º°

Á¦8Àå ºÏ¹ÌÀÇ ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ºÐ¼® : Àü°³º°

Á¦9Àå ºÏ¹ÌÀÇ ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ºÐ¼® : ±â¾÷ ±Ô¸ðº°

Á¦10Àå ºÏ¹ÌÀÇ ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ºÐ¼® : Çüź°

Á¦11Àå ºÏ¹ÌÀÇ ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ºÐ¼® : ±â´Éº°

Á¦12Àå ºÏ¹ÌÀÇ ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ºÐ¼® : ÃÖÁ¾ »ç¿ëÀÚº°

Á¦13Àå ºÏ¹ÌÀÇ ¾à¹°°¨½Ã ¹× ÀǾàǰ ¾ÈÀü¼º ¼ÒÇÁÆ®¿þ¾î ½ÃÀå : ±¹°¡º° ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

Á¦15Àå ¾÷°è Á¤¼¼

Á¦16Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦17Àå ºÎ·Ï

SHW
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The North American pharmacovigilance and drug safety software market was valued at approximately $100.03 million in 2023 and is projected to grow to about $182.72 million by 2031, reflecting a compound annual growth rate (CAGR) of 7.8% during the forecast period from 2023 to 2031.

Increasing Incidence of Adverse Drug Reactions

The rise in adverse drug reactions (ADRs) is a significant factor driving the growth of the pharmacovigilance and drug safety software market in North America. The prevalence of chronic diseases is on the rise, leading to an increase in the number of medications prescribed, which in turn raises the potential for ADRs. Given that all medications can cause adverse reactions, conducting a thorough risk-benefit analysis is crucial whenever a drug is prescribed. ADRs pose a considerable challenge in contemporary healthcare, especially with the increasing complexity of treatment regimens, an aging population, and the prevalence of multiple chronic conditions.

Pharmacovigilance software plays a vital role in enabling healthcare providers and pharmaceutical companies to systematically collect, analyze, and report data related to ADRs. This software is essential for addressing the challenges posed by ADRs, as evidenced by the data from the US Food and Drug Administration's Adverse Event Reporting System (FAERS), which reported over 1.25 million severe adverse cases and more than 175,000 deaths in 2022 alone.

The interaction of certain medications, such as theophylline with macrolide antibiotics and increased vitamin K consumption, has been linked to ADRs. As the number of reported ADRs continues to rise, there is increasing pressure on pharmaceutical companies, healthcare providers, and regulatory bodies to enhance drug safety monitoring and reporting processes. Pharmacovigilance and drug safety software streamline the detection, assessment, and prevention of adverse effects, facilitating quicker response times and more accurate risk assessments. Consequently, the growing incidence of ADRs is a key driver of market growth in pharmacovigilance and drug safety software.

Overview of the North American Market

The North American pharmacovigilance and drug safety software market is segmented into the United States, Canada, and Mexico. North America is recognized as an early adopter of regulations concerning pharmaceutical and drug safety. Additionally, the region is witnessing a surge in digitization within the pharmaceutical sector. According to Canada Health Infoway, pharmaceutical companies in Canada are increasingly adopting digital health services, which is expected to drive demand for pharmacovigilance and drug safety software in the coming years. The growing digitization in the pharmaceutical industry is anticipated to enhance the need for effective monitoring of pharmaceutical drugs, thereby increasing the demand for pharmacovigilance solutions.

As the volume of reported adverse events rises, pharmacovigilance and drug safety professionals face greater challenges in accurately and efficiently evaluating this data. The implementation of advanced technologies is crucial to alleviate the workload of these professionals while ensuring precise and systematic analysis of adverse event data.

Market Segmentation Analysis

The North American pharmacovigilance and drug safety software market can be categorized based on various factors, including offering, deployment, enterprise size, form, functionality, end user, and country.

1. Offering: The market is divided into software and services, with the software segment holding a larger share in 2023.

2. Deployment: The market is further segmented into cloud-based and on-premises solutions, with cloud solutions dominating the market share in 2023.

3. Enterprise Size: The market is categorized into large enterprises and small to medium-sized enterprises (SMEs), with large enterprises holding a significant share in 2023.

4. Form: The software is available in standard and customized forms, with the standard form being more prevalent in the market.

5. Functionality: The market includes various functionalities such as signal and risk management, issue tracking, case management, clinical safety management, quality and compliance, and healthcare analytics, with signal and risk management being the largest segment in 2023.

6. End User: The primary end users include pharmaceutical and biotechnology companies, contract research organizations, and business process outsourcing firms, with pharmaceutical and biotechnology companies leading the market share.

7. Country: The market is segmented into the US, Canada, and Mexico, with the US dominating the market in 2023.

Key Players in the Market

Several prominent companies are active in the North American pharmacovigilance and drug safety software market, including Veeva Systems Inc., IQVIA Holdings Inc., AB Cube S.A.S., ArisGlobal LLC, Oracle Corp, Max Application, ICON Plc, Cognizant Technology Solutions Corp, Accenture Plc, Syneos Health Inc., Genpact Ltd., Laboratory Corp of America Holdings, Parexel International Corp, Qinecsa Solutions, and Clinevo Technologies. These companies are at the forefront of developing innovative solutions to enhance drug safety and pharmacovigilance practices in the region.

Table Of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. North America Pharmacovigilance and Drug Safety Software Market Landscape

5. North America Pharmacovigilance and Drug Safety Software Market - Key Market Dynamics

6. North America Pharmacovigilance and Drug Safety Software Market - Analysis

7. North America Pharmacovigilance and Drug Safety Software Market Analysis - by Offering

8. North America Pharmacovigilance and Drug Safety Software Market Analysis - by Deployment

9. North America Pharmacovigilance and Drug Safety Software Market Analysis - by Enterprise Size

10. North America Pharmacovigilance and Drug Safety Software Market Analysis - by Form

11. North America Pharmacovigilance and Drug Safety Software Market Analysis - by Functionality

12. North America Pharmacovigilance and Drug Safety Software Market Analysis - by End User

13. North America Pharmacovigilance and Drug Safety Software Market - Country Analysis

14. Competitive Landscape

15. Industry Landscape

16. Company Profiles

17. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â